InnoCan Pharma Corporation
INNO.CN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.55M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.55 Million |
|---|---|
| Enterprise Value | $3.77 Million |
| Earnings per Share | $-0.25 |
| Beta | -0.22 |
| Outstanding Shares | 4,498,772 |
Return
| Return on Equity | -19.67% |
|---|---|
| Return on Assets | -9.12% |
| Return on Invested Capital | -13.26% |
Valuation & Multiples
| P/E Ratio | -6.54 |
|---|---|
| PEG | 6.93 |
| Price to Sales | 0.38 |
| Price to Book Ratio | 1.9 |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | -3.39 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 25, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About InnoCan Pharma Corporation
11 employees
CEO: Iris Bincovich
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United S...